Agios Pharmaceuticals financials
$33.30−0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0.00 | $0.00 | — | $94.4M | $43.0M | $69.9M |
| Gross profit | $47.7M | $32.3M | $23.9M | $12.5M | $0.00 | $0.00 | — | $93.0M | $43.0M | $69.9M |
| Gross margin | 88.3% | 88.6% | 89.3% | 88.0% | — | — | — | 98.5% | 100.0% | 100.0% |
| Operating income | -$472.1M | -$425.7M | -$391.5M | -$389.0M | -$378.4M | -$335.9M | -$316.3M | -$362.5M | -$320.8M | -$201.0M |
| Net income | -$412.8M | $673.7M | -$352.1M | -$231.8M | $1.60B | -$327.4M | -$411.5M | -$346.0M | -$314.7M | -$198.5M |
| Net margin | −764.0% | 1845.9% | −1312.6% | −1627.8% | — | — | — | −366.6% | −731.6% | −284.0% |
| Diluted EPS | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | $-6.03 | $-6.75 | $-5.07 |
| EBITDA | -$467.0M | -$420.1M | -$384.9M | -$380.5M | -$359.6M | -$317.1M | -$308.2M | -$355.3M | -$314.4M | -$195.3M |
| Operating cash flow | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M | -$290.8M | -$370.6M | -$304.4M | -$285.2M | $38.6M |
| Free cash flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M | -$304.9M | -$382.6M | -$311.4M | -$289.9M | $28.6M |
| Diluted shares | 58.0M | 57.9M | 55.7M | 54.8M | 60.4M | 69.0M | 60.0M | 57.4M | 46.6M | 39.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $89.1M | $76.2M | $88.2M | $139.3M | $203.1M | $127.4M |
| Short-term investments | $765.3M | $817.5M | $688.7M | $643.9M | $816.9M | $445.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $607.0K | $648.0K |
| Total assets | $1.30B | $1.66B | $937.1M | $1.24B | $1.44B | $853.0M |
| Total liabilities | $104.1M | $122.2M | $126.1M | $137.9M | $145.8M | $453.5M |
| Shareholders' equity | $1.19B | $1.54B | $811.0M | $1.10B | $1.29B | $399.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology